Our Focus

We can't eliminate epidemics, but we can minimize their impact.

Political instability, proliferation of global transportation, population expansion, increasing demand for proteins and ecological change are all contributing to increased infectious disease risk. That's why we partner with businesses and governments worldwide to identify and track pathogens from their source, then contextualize the risk based on socioeconomic, political, environmental and other factors.

Play product video
Our Science

Our analytics enable innovative insurance products.

Years of deep scientific leadership and portfolio-specific asset analysis are our foundation for creating sustainable business tools for a volatile world. By understanding marketplace mechanisms and our partners' needs, we help identify risk transfer and intervention opportunities that would otherwise remain hidden.

Learn more
Novel Coronavirus Cases (12 December 2019 - 20 February 2020)
Ebola Virus Cases (30 April 2018 - 18 February 2020)
Cholera Cases (27 April 2017 - 11 February 2020)
MERS Coronavirus Cases 2020 YTD (thru 17 February 2020)
  • Novel Coronavirus
  • Ebola Virus
  • Cholera
  • MERS Coronavirus

Since December 2019, Chinese authorities have been tracking an outbreak of novel coronavirus centered in Wuhan, Hubei Province. Travel-related cases have also been identified in other countries. According to Chinese officials, the primary clinical manifestations include, fever, cough, chest tightness, and dyspnea but some patients have developed difficulty breathing, pneumonia, and organ failure. Early investigations suggested animal-to-human spread; however, a growing number of cases have not had exposure to animal markets, suggesting that sustained human-to-human transmission is occurring. Cases have been reported among health care workers. For additional information, including up-to-date outbreak details, visit Metabiota's Epidemic Tracker.


Hong Kong Centre for Health Protection (2020). Novel Coronavirus - China. Retrieved from https://www.chp.gov.hk/files/pdf/statistics_of_the_cases_novel_coronavirus_infection_en.pdf (7 February 2020).

Over the last four decades, the Democratic Republic of Congo has experienced eight Ebola outbreaks. The most recent epidemic took place in May 2017 in the health zone of Likati, province of Bas-Uele. The ongoing epidemic is located in the Bikoro health zone, located in Equateur province, in the western Democratic Republic of the Congo and on the border with the Republic of Congo.


WHO (2019). Ebola virus disease - Democratic Republic of the Congo. Retrieved from https://www.who.int/csr/don/22-august-2019-ebola-drc/en/ (22 August 2019).

Cholera is an acute diarrhoeal disease caused by Vibrio cholerae that can kill within hours if left untreated. Researchers have estimated that each year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide due to cholera. 


WHO (2017). Cholera fact sheet. Retrieved from http://www.who.int/mediacentre/factsheets/fs107/en/ (27 Nov 2017).

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a novel coronavirus (Middle East respiratory syndrome coronavirus, or MERS-CoV) that was first identified in Saudi Arabia in 2012. Typical MERS symptoms include fever, cough and shortness of breath. Some laboratory-confirmed cases of MERS-CoV infection are reported as asymptomatic, meaning that they do not have any clinical symptoms, yet they are positive for MERS following a laboratory test.


WHO (2017). Middle East respiratory syndrome coronavirus fact sheet. Retrieved from http://www.who.int/mediacentre/factsheets/mers-cov/en/ (27 Nov 2017).

Our Platform

Insights must be actionable, global and dynamic.

We can confront infectious disease risk for a simple reason — we have best-in-class models informed by the most comprehensive epidemiological database ever created. Our platform processes hundreds of data sources covering historical pandemics to emerging outbreaks.

Learn more
Our Mission

We strive to make the world more resilient to epidemics.

We believe that working with the insurance industry and governmental organizations on improved techonologies is one of the best ways to help mitigate the impact of infectious diseases.


Metabiota's offering enables reinsurers and insurers to accurately quantify complex infectious disease risk. Whether it's to create novel insurance products or improve capital utilization and enterprise risk management, Metabiota partners with customers to improve insurability through better understanding and analysis of underlying exposure.


Government agencies responsible for outbreak response planning and implementation leverage Metabiota's platform to assess preparedness and conduct what-if analyses to ensure readiness for events of varying impact.